Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Other 1

Conditions

Tuberous Sclerosis 5Seizures 4Marijuana Abuse 3Colonic Neoplasms 3Breast Neoplasms 3Sturge-Weber Syndrome 2Nausea 2Lennox Gastaut Syndrome 2Glioblastoma 2Epilepsies, Myoclonic 2Anxiety Disorders 2Vomiting 1Tuberous Sclerosis 2 1Tuberous Sclerosis 1 1Spasms, Infantile 1Solid Tumor 1Rectal Neoplasms 1Prostatic Neoplasms 1Parasomnias 1Pancreatic Neoplasms 1Pain 1Neoplasms 1Multiple Myeloma 1Liver Neoplasms 1Liver Cirrhosis 1Gallbladder Neoplasms 1Epilepsy 1Dysgeusia 1Drug Resistant Epilepsy 1Colorectal Neoplasms 1

Interventions

Standard of Care 1Specimen Handling 1Practice Guidelines as Topic 1Methods 1Massage 1Interviews as Topic 1Educational Status 1Early Intervention, Educational 1Cannabidiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Chemotherapy-Induced Peripheral Neuropathy × Cannabidiol × Clear all
NCT05388058 2026-01-16

Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

Mayo Clinic

Phase 2 Completed
40 enrolled 15 charts
OtherOther solid neoplasm

Chemotherapy-Induced Peripheral Neuropathy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡